Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Enterprise Therapeutics Appoints CEO | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Enterprise Therapeutics Appoints CEO

Ford is a biotechnology entrepreneur with 18 years of drug discovery and development experience

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dr. John Ford has been appointed chief executive officer of Enterprise Therapeutics. The company is developing novel muco-regulatory therapies for Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF) and severe asthma.
 
Dr. Ford has more than 18 years of ion channel research, drug discovery and development experience. He is a biotechnology entrepreneur who co-founded Xention, Ario Pharma and Metrion Biosciences. Recently, he was a member of the executive team at Dezima, which developed TA-8995 for dyslipidaemia. Dezima was sold to Amgen in 2015 for as much as $1.6 billion.  
 
Dr. Peter Finan, chairman Enterprise Therapeutics, said, “John’s experience in ion channels, drug development, and biotech fundraising, position him uniquely to lead Enterprise Therapeutics moving forward. His expertise will complement the existing team and we are thrilled to have him on board.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics